AZR
NASDAQAzora Therapeutics Inc.
Azora Therapeutics Inc. (AZR) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 6 wire items for AZR, including 3 insider trades, 1 analyst rating and 1 13D/G filing. The most recent was published Nov 5, 2026.
Price$3.92-0.96 (-19.57%)
2026-08-062026-11-06
Financial highlights
Full financials- Net income, TTM
- -$57.80M
- Cash
- $28.71M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks6+100%
2026-05-102026-11-01
Mix690d
- Insider3(50%)
- Analyst1(17%)
- 13D/G1(17%)
- Leadership1(17%)
Activity · 52 weeks64 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
6 items- PRAzora Therapeutics Appoints Board of Directors with Extensive Drug Development and Inflammatory Bowel Disease ExpertiseLOS ANGELES, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Azora Therapeutics, Inc. (NASDAQ:AZR), a biopharmaceutical company developing treatments for serious inflammatory diseases, today announced it has established a five-member board of directors with deep drug development experience, a track record of FDA approvals, expertise in public-company governance, and clinical capabilities in gastroenterology and immunology. "The depth and diversity of expertise represented in our board of directors position Azora for success in advancing AT177 into the clinic and through proof of concept as we aim to restore intestinal health for people living with ulcerative colitis," said Matt Davidson, Ph.D., Co-foun
- INSIDERPresident and CEO Davidson Matt converted options into 626,252 shares, increasing direct ownership by 179% to 819,018 units (SEC Form 4)4 - Azora Therapeutics, Inc. (DE) (0001513525) (Issuer)
- INSIDERChief Strategy Officer Saiki Julie converted options into 626,252 shares, increasing direct ownership by 463% to 761,636 units (SEC Form 4)4 - Azora Therapeutics, Inc. (DE) (0001513525) (Issuer)
- INSIDERSEC Form 4 filed by Large owner Coastlands Capital Lp4 - Azora Therapeutics, Inc. (DE) (0001513525) (Issuer)
- 13D/GAmendment: SEC Form SCHEDULE 13G/A filed by Azora Therapeutics Inc.SCHEDULE 13G/A - Azora Therapeutics, Inc. (DE) (0001513525) (Subject)
- ANALYSTTD Cowen initiated coverage on AztarTD Cowen initiated coverage of Aztar with a rating of Buy
AZR FAQ
10 questionsWhat does Azora Therapeutics Inc. do?
Azora Therapeutics Inc. is a biopharmaceutical company focused on developing treatments for serious inflammatory diseases. The company was spun out of Stanford University after being incubated in the translational medicine SPARK program. Azora owns the worldwide royalty-free rights to its technology, which is based on the development of potential best-in-class oral agonists of the aryl hydrocarbon receptor. Azora's lead program is AT177, a proprietary colon-targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure in development...What is the latest news on AZR?
In the last 30 days Quantisnow tracked 6 wire items for AZR: 3 insider trades, 1 analyst rating, 1 13D/G filing and 1 leadership change. The most recent was published on November 5, 2026.Is AZR profitable?
No. Azora Therapeutics Inc. reported a net loss of $57.80M for the twelve months ended Jun 30, 2026.How much cash and debt does AZR have?
Azora Therapeutics Inc. reported $28.71M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does AZR stock trade?
Azora Therapeutics Inc. (AZR) is listed on NASDAQ.What sector and industry is AZR in?
Azora Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Azora Therapeutics Inc. go public?
Azora Therapeutics Inc. (AZR) completed its IPO in 2018.What are analysts saying about AZR?
Azora Therapeutics Inc. has had 1 recent analyst action on file. The most recent action was from TD Cowen: Buy on 2026-11-02.What companies are similar to AZR?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare AZR side-by-side with any of them on Quantisnow.How can I track AZR on Quantisnow?
Quantisnow aggregates Azora Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AZR to receive live email and push alerts on every new disclosure.